Press Releases

BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London

NEW YORK and LONDONMay 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, president and CEO, will provide an update on the Company’s two clinical trials of NurOwn® (the Phase 3 study in amyotrophic lateral sclerosis (ALS) and the  Phase 2 study in Progressive Multiple Sclerosis (MS), during the 14th Annual World Advanced Therapy and Regenerative Medicine Congress, taking place in London, England.  Mr. Lebovits will be participating in a Round Table session titled: “Stem Cells for Neurological Applications,” and then join a Panel discussion titled: “Clinical Development of Next Generation Cellular Therapeutics.” Mr. Lebovits will also be hosting institutional investor and industry leader partnering meetings during the Congress.

Round Table: Stem Cells for Neurological Applications
Date: Thursday, May 16
Time: 12:10pm BST
Location: Business Design Centre, London (Technology and Strategy Roundtables – Table 4)
Presenter: Chaim Lebovits, Chief Executive Officer
Panel Discussion: Clinical Development of Next Generation Cellular Therapeutics
Date: Thursday, May 16
Time: 02.35pm BST
Location: Business Design Centre, London (Clinical Trials: Cell Therapy & CAR-T -  Track 4)
Presenter: Chaim Lebovits, Chief Executive Officer

About the World Advanced Therapies & Regenerative Medicine Congress
The 14th annual World Advanced Therapies & Regenerative Medicine Congress will bring together 1000+ attendees and explores the rapidly developing world of next generation therapeutics and advanced therapy medical products (ATMPs). From clinical development to pricing, reimbursement and market access this congress will bring the most exciting case studies and new data for immunotherapy, cell therapy, gene therapy, CARs and bioprocessing. Experts in every area will help companies tackle the process and regulatory hurdles of developing all new therapeutic formats all the way through manufacture and into the clinic.  This year’s conference will take place May 15 – 17 at the Business Design Center, London.

About BrainStorm Cell Therapeutics Inc.   
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm is currently enrolling a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company's website at

Safe-Harbor Statements
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.


Uri Yablonka 
Chief Business Officer 
BrainStorm Cell Therapeutics Inc. 
Phone: 646-666-3188

Michael Levitan 
Solebury Trout 
Phone: 646-378-2920

Sean Leous 
Westwicke Public Relations 
Phone: 646-677-1839




Source: BrainStorm Cell Therapeutics Inc.

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds